Arca
Skip to content
Tools
Tools

Constipation

Drug research and approvals for constipation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 100 studies of constipation are recruiting on ClinicalTrials.gov, Health Canada has authorized 17 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 5 authorised medicines for it.

  • Recruiting worldwide: 100
  • Trials authorized in Canada: 17
  • FDA orphan approvals: 0
  • EU medicines: 5

Recruiting Now

Newest start dates first, of 100 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

31 approved, 10 in phase 3, 16 in phase 2, 8 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Prucalopride, Lubiprostone, Naloxegol, Polyethylene glycol 3350, Methylnaltrexone, Polyethylene glycol, Plecanatide, Bisacodyl, Senna, Linaclotide, Tegaserod, Lactulose, Docusate, Alvimopan, Naldemedine, Naloxone, Glycerin, Picosulfuric acid, Mannitol, Magnesium oxide, Sorbitol, Tenapanor, Oxyphenisatine, Phenolphthalein, Danthron, Sodium phosphate, dibasic, anhydrous, Lactitol, Methylcellulose, Cascara sagrada, Castor oil, Mineral oil

Bevenopran
Phase 3 Mu opioid receptor antagonist
Elobixibat
Phase 3 Ileal bile acid transporter inhibitor
Mosapride
Phase 3 Serotonin 3 (5-HT3) receptor antagonist
Polyethylene glycol 4000
Phase 3 Laxative
Pectin
Phase 3
Simeticone
Phase 3 Anti-gas, surfactant
Acesulfame
Phase 3
Wheat bran
Phase 3
Axelopran
Phase 2 Mu opioid receptor antagonist
Methylsamidorphan
Phase 2 Mu opioid receptor antagonist
Lactobacillus acidophilus
Phase 2 Probiotic
Relenopride
Phase 2 Serotonin 4 (5-HT4) receptor agonist
Hydromorphone
Phase 2 Mu opioid receptor agonist
Vancomycin
Phase 2 Peptidoglycan inhibitor
Alfuzosin
Phase 2 Adrenergic receptor alpha-1 agonist
Octreotide
Phase 2 Somatostatin receptor agonist
Pradigastat
Phase 2 Diacylglycerol O-acyltransferase 1 inhibitor
Itopride
Phase 2 Dopamine D2 receptor antagonist
Dolcanatide
Phase 2 Heat-stable enterotoxin receptor agonist
Alcohol
Phase 2
TU-100
Phase 2
Codeine
Phase 1 Opioid receptors; mu/kappa/delta agonist
Morphine
Phase 1 Mu opioid receptor agonist
Moxifloxacin
Phase 1 Topoisomerase IV inhibitor
Quinidine
Phase 1 Sodium channel alpha subunit blocker

Showing the 30 furthest along of 34 in trials.

How Its Trials Ended

967 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 247 whose ending is known, 58% met their primary endpoint, 6% missed it and 35% stopped early.

  • Completed, result not reported45847%
  • Met its primary endpoint14415%
  • Ongoing13714%
  • Status unknown12513%
  • Stopped: other or unclear515%
  • Stopped: enrollment or feasibility202%
  • Missed its primary endpoint162%
  • Stopped: sponsor or business decision81%
  • Stopped: lack of efficacy40%
  • Stopped: funding30%
  • Stopped: safety10%

Trials Authorized in Canada

The 10 newest of 17; search them all in Canada trials
Jul 7, 2020A phase 2, randomized, double-blind, placebo-controlled, sequential, ascending, multidose study to evaluate the safety and efficacy of linaclotide in pediatric…Constella (linaclotide)AbbVieClosed
Mar 5, 2020A phase 3, open-label, long-term safety study of oral linaclotide administered to pediatric participants with functional constipation (fc) or irritable bowel…Linaclotide (constella)AbbVieOngoing
Oct 24, 2019A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy study of linaclotide administered orally to children,…LinaclotideAbbVieClosed
Dec 30, 2015Implementation of high-resolution manometry (hrcm) to improve the care of children with refractory chronic constipationprucalopride/ bisacodylHamilton Health Sciences CorporationPending
Dec 8, 2015A multicenter, randomized, double-blind, placebo-controlled, parallel group, safety and efficacy study of a range of linaclotide doses administered orally to…LinaclotideForest Research InstituteClosed
Dec 8, 2015A multicenter, randomized, double-blind, placebo-controlled, parallel group, safety and efficacy study of a range of linaclotide doses administered orally to…LinaclotideForest Research InstituteClosed
May 14, 2014A multicentre, long-term safety, efficacy and pharmacokinetics study of lubiprostone in paediatric subjects aged >=6 to <18 years with functional constipationAmitiza (lubiprostone)MallinckrodtClosed
Mar 12, 2014A multicentre, randomised, placebo-controlled, double-blinded study of the efficacy, safety, and pharmacokinetics of lubiprostone in paediatric subjects aged >…LubiprostoneMallinckrodtClosed
Mar 7, 2014An open-label extension (ole), long-term safety and tolerability study of plecanatide in patients with chronic idiopathic constipation (cic)PlecanatideSynergy Pharmaceuticals IncOngoing
Mar 7, 2014A randomized, 12-week, double-blind, placebo-controlled study to assess the safety and efficacy of plecanatide (3.0 and 6.0 mg) in patients with chronic…PlecanatideSynergy Pharmaceuticals IncClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Sep 16, 2002Human gammaglobulinTreatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism…Latona Life Sciences, Inc.Designated
Jun 17, 1996MethylnaltrexoneTreatment of chronic opioid-induced constipation unresponsive to conventional therapy.Progenics Pharmaceuticals, Inc.Designated

Medicines Authorised in the EU

Newest first
Feb 18, 2019RizmoicNaldemedineShionogi B.V.EMA ↗
Dec 7, 2014MoventigNaloxegolGrunenthal GmbHEMA ↗
Nov 26, 2012ConstellaLinaclotideAbbVie Deutschland GmbH & Co. KGEMA ↗
Oct 14, 2009ResolorPrucaloprideTakeda Pharmaceuticals International AG IrelandEMA ↗
Jul 1, 2008RelistorMethylnaltrexone bromideBausch Health Ireland LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.